Share Name Share Symbol Market Type Share ISIN Share Description
Redx Pharma LSE:REDX London Ordinary Share GB00BSNB6S51 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 32.375p 0.00p 0.00p - - - 0 06:30:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -15.4 -19.8 - 40.95

Redx Pharma Share Discussion Threads

Showing 151 to 173 of 175 messages
Chat Pages: 7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
03/9/2017
09:56
Sunday Times article today - Headline MOULTON BURNT IN BIOTECH COLLAPSE - Interest ST comment attributed to JM "With the benefit of hindsight it looked to be a prospectus which failed to mention the fact that they had immediatly due cash" -
pugugly
02/8/2017
09:01
Hmmm, a chunk of the IP gets sold off for $40million to get the company out of admin. Be interesting to see what it sinks to when it opens up.
whitebicycle
22/6/2017
07:32
News but no news...they had £5m in cash end of March too. Unbelievable.
molatovkid
26/5/2017
13:18
Ok...rang someone connected with the company and if they come to some arrangement on the money, we get un-suspended and back in play again.
king kong dong
26/5/2017
09:26
Just rang the Head of Investor Relations try and find out what is happening here.... don't suppose they will tell me a great deal, but you have to try.
king kong dong
26/5/2017
09:08
So they raised £12M a few months back and now dont have the cash to repay a £2M loan + interest. Something stinks...
phowdo
24/5/2017
21:05
Not good anyway you read it. Just hope they can retain the IP and survive.
whitebicycle
15/5/2017
07:50
Preclinical data for reversible BTK inhibitor RXC005 presented at the 17th International Workshop of Chronic Lymphocytic Leukemia Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that preclinical efficacy data in mouse-models for its development candidate, RXC005, a reversible BTK inhibitor, has been presented in a poster session at the 17th International Workshop of Chronic Lymphocytic Leukemia (iwCLL) biennial meeting in New York City, U.S. on 14 May, 2017. The poster, entitled "RXC005, a Potent and Selective, Reversible BTK Inhibitor Targeting both Wild-type and Mutant C481S BTK with Potent Efficacy in ABC-DLBCL Xenograft Mouse Models", demonstrated that RXC005 successfully inhibits wild-type BTK and C481S mutant BTK, as well as B-Cell Receptor signalling in ABC-DLBCL cell lines and importantly primary CLL cells. RXC005 was also shown to be highly selective and exhibits improved target specificity against other Tec and Src kinase family members. RXC005 demonstrated significant efficacy in ABC-DLBCL xenograft mouse models such as TMD8 and OCI-Ly10 cell lines.The poster can be found on the Company's website www.redxpharma.comDr Neil Murray, Chief Executive Officer of Redx Pharma, commented: "We are delighted to have presented further potent efficacy data for one of our lead development candidates, RXC005, at the prestigious iwCLL event in front of our peers and contemporaries." Dr Richard Armer, Chief Scientific Officer of Redx Pharma, commented: "The data presented is further validation of RXC005's potential to target both wild-type and mutant BTK, an important emerging resistance mechanism in patients with CLL progression following ibrutinib treatment. With good target engagement demonstrated in the PK/PD studies and efficacy in mouse-models, we look forward to filing an IND/CTA in late 2017 to take RXC005 into the clinic."
mattboxy
02/4/2017
18:15
Nice post and I 100% agree.....
molatovkid
02/4/2017
09:29
The market is totally missing the significance of the a) change in company focus b) fundraising c) the CABB-X funding for anti-infectives (a)shows the management now reckon they have the product base for a PROFITABLE long term base. (b) a war chest is in place to deliver (a). The assumption a few weeks ago was that the anti-isomerase antibiotics was peripheral and would be sold off. After all what chance did it have against 117 other novel antibiotic candidates being reviewed by the US govt for funding. But the yanks have decided it is a WINNER....THE ONLY NON UK PRODUCT IN TRUMPS USA that they were HAPPY to fund... So with cash in the bank which has depressed share price a leaner structure and a massive vote if confidence for the peripheral product and 2 world class product ranges going into trials there is only one way the share price is going over coming months DYOR GLA
hlp_4u
31/3/2017
06:59
Nice $1m to add to the coffers
king kong dong
16/3/2017
10:30
RedX Pharma CEO Neil Murray will be presenting to investors at the upcoming Proactive One2One Forum on 23rd March from 6pm at the Chesterfield Mayfair Hotel. For details and registration, please click here: https://tinyurl.com/zupvh3j
aim_trader
06/3/2017
07:44
wrong thread sorry .
markie225
27/2/2017
14:42
Rocket launcher tech here.....blast off in 1-2 months
mbmiah
17/2/2017
11:02
At guess no much will happen until the open offer is completed I am in as this is e very risky one but immense potential
jovi1
10/2/2017
12:02
yep I am interested! Just looked for comments on the recent placing. nada here? Unusual to see an Aim stock fund raise and not get hammered. Hope its a good sign
shaker44
03/2/2017
22:44
Is no one interested in this share???
judijudi
14/11/2016
13:24
Specsavers Dave
ttg100
11/11/2016
11:52
Do my eyes deceive me or is the share price rising?
investordave
20/10/2016
07:44
good news today!
molatovkid
19/10/2016
17:53
Patience as I am now buying in and with a yoy record of 178% the ditch of GDR trading house and the fact the rockerfeller family bought in recently is an absolute plus.
francis55
19/10/2016
13:17
And the chart is saying 35p
irishlass2
19/10/2016
12:39
placing prospectus must be doing the rounds here
pugg1ey
Chat Pages: 7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170919 15:19:13